| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825111 | Clinical Therapeutics | 2015 | 16 Pages |
Abstract
Despite the universal development of antidrug antibodies, elosulfase alfa treatment was both safe and well tolerated and immunogenicity was not associated with reduced treatment effect. ClinicalTrials.gov identifier: NCT01275066. (Clin Ther.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Becky PhD, Troy BS, Kelly MS, Lynne PhD, Yulan PhD, Donald G. PhD, Pamela MD, Christine MD, Adam J. MD, PhD, Ke PhD, Charles A. PhD,